Gabapentin
Product Images NDC 50090-5045

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-5045). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Line graph depicting the mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, with a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decreasing pain score trend relative to placebo, which remains relatively steady.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period, comparing placebo and two dosage groups of gabapentin (1800 mg/day and 2400 mg/day). The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease more in the gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) at different dosages in two studies. The y-axis shows percentage from 0 to 100%, highlighting higher responder rates for Gabapentin doses versus placebo with statistical significance indicated.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A pharmacokinetic equation expressing creatinine clearance (CLCr) as a function of age, weight, serum creatinine levels, and a sex adjustment factor for females. The formula calculates CLCr in mL/min based on these patient variables.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram showing the molecular configuration of gabapentin, an active pharmaceutical ingredient used in various medications.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A plotted chart showing the percentage difference on the y-axis against daily dose in milligrams on the x-axis, depicting data points from three studies labeled a, b, and c. The chart includes data points at approximately 600, 900, 1200, and 1800 mg daily doses with corresponding percentage differences ranging around 7% to 18%.*

FDA Label Image

Label Image (Lbl500905045)

Label for Gabapentin 800 mg film-coated tablets by A-S Medication Solutions. The label indicates each tablet contains 800 mg of gabapentin with 90 tablets per package. Storage instructions advise keeping the product between 68 and 77 degrees Fahrenheit. The label includes NDC 50090-5045-1 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.